Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

Date publication

octobre 2017

Journal

Neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28916537

Résumé

To characterize the reversibility of natalizumab-mediated changes in pharmacokinetics/pharmacodynamics in patients with multiple sclerosis (MS) following therapy interruption.

Mots clés

Adult, Double-Blind Method, Female, Follow-Up Studies, Humans, Immunologic Factors, blood, Integrin alpha4, blood, Lymphocyte Count, Lymphocyte Subsets, immunology, Male, Middle Aged, Multiple Sclerosis, blood, Natalizumab, blood, Retrospective Studies, Secondary Prevention, Treatment Outcome, Vascular Cell Adhesion Molecule-1, blood

Référence

Neurology. 2017 Oct 10;89(15):1584-1593